

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q95907

Kenji MIYAMOTO, et al.

Appln. No.: 10/585,417

Group Art Unit: 1623

Confirmation No.: 4711

Examiner: Scarlett Y. GOON

Filed: April 10, 2007

For: HYALURONIC ACID DERIVATIVE AND DRUG CONTAINING THE SAME

STATEMENT OF SUBSTANCE OF INTERVIEW

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Please review and enter the following remarks summarizing the interview conducted on
September 22, 2010:

REMARKS

An Examiner's Interview Summary Record (PTO-413) dated September 28, 2010 has
been received.

During the interview, the following was discussed:

1. **Brief description of exhibits or demonstration:** None
2. **Identification of claims discussed:** All of the pending claims
3. **Identification of art discussed:** Tamura et al. (EP 1082963 A1;) and Perioli et al. (see PTO-892, Ref. U).
4. **Identification of principal proposed amendments:** Applicants' representatives and the Examiners discussed the Amendment Under 37 C.F.R. § 1.111 filed August 25, 2010.

5. **Brief Identification of principal arguments:** Applicant's representatives explained why claim 36 is not obvious in view of the applied combination of references. Applicants did not agree that the Examiner had established a *prima facie* of obviousness. However, Applicants asserted that if, *arguendo*, a *prima facie* case of obviousness had been established, the Declaration submitted on August 25, 2010 demonstrated non-obviousness. The Declaration submitted on August 25, 2010 was discussed.


6. **Indication of other pertinent matters discussed:** The Examiner proposed claim amendments to improve formality of the claims.

7. **Results of Interview:** Agreement was reached. The Examiner indicated that a Notice of Allowance should be expected.

It is respectfully submitted that the instant STATEMENT OF SUBSTANCE OF INTERVIEW complies with the requirements of 37 C.F.R. §§1.2 and 1.133 and MPEP §713.04.

It is believed that no petition or fee is required. However, if the USPTO deems otherwise, Applicant hereby petitions for any extension of time which may be required to maintain the pendency of this case, and any required fee, except for the Issue Fee, for such extension is to be charged to Deposit Account No. 19-4880.

Respectfully submitted,



Yan Lan
Registration No. 50,214

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

65565

CUSTOMER NUMBER

Date: September 29, 2010